ImmunoGen, Inc.
IMGN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | -0.06 | 0.32 | 0.20 |
| FCF Yield | -18.38% | -15.11% | -7.00% | -12.04% |
| EV / EBITDA | -4.63 | -8.61 | -44.01 | -9.26 |
| Quality | ||||
| ROIC | -95.55% | -29.20% | -56.93% | -57.17% |
| Gross Margin | 99.84% | 100.00% | 13.38% | -39.20% |
| Cash Conversion Ratio | 1.03 | 1.03 | 1.77 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.32% | -5.31% | 34.96% | 4,349,162.22% |
| Free Cash Flow Growth | 0.00% | -190.64% | 12.80% | 46.87% |
| Safety | ||||
| Net Debt / EBITDA | 1.20 | 3.70 | 13.72 | 2.27 |
| Interest Coverage | -53.04 | -9.51 | -5.84 | -5.43 |
| Efficiency | ||||
| Inventory Turnover | -0.01 | 0.00 | -3.77 | -3.51 |
| Cash Conversion Cycle | -154,102.41 | 72.77 | -65.14 | -14.90 |